Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

624 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
The Prognostic Effect of IKZF1 Deletions in ETV6::RUNX1 and High Hyperdiploid Childhood Acute Lymphoblastic Leukemia.
Østergaard A, Enshaei A, Pieters R, Vora A, Horstmann MA, Escherich G, Johansson B, Heyman M, Schmiegelow K, Hoogerbrugge PM, den Boer ML, Kuiper RP, Moorman AV, Boer JM, van Leeuwen FN. Østergaard A, et al. Among authors: heyman m. Hemasphere. 2023 May 4;7(5):e875. doi: 10.1097/HS9.0000000000000875. eCollection 2023 May. Hemasphere. 2023. PMID: 37153875 Free PMC article.
In vitro drug resistance and prognostic impact of p16INK4A/P15INK4B deletions in childhood T-cell acute lymphoblastic leukaemia.
Ramakers-van Woerden NL, Pieters R, Slater RM, Loonen AH, Beverloo HB, van Drunen E, Heyman M, Moreno TC, Rots MG, van Wering ER, Kamps WA, Janka-Schaub GE, Veerman AJ. Ramakers-van Woerden NL, et al. Among authors: heyman m. Br J Haematol. 2001 Mar;112(3):680-90. doi: 10.1046/j.1365-2141.2001.02586.x. Br J Haematol. 2001. PMID: 11260073 Free article.
Outcome of ETV6/RUNX1-positive childhood acute lymphoblastic leukaemia in the NOPHO-ALL-1992 protocol: frequent late relapses but good overall survival.
Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Rosenquist R, Swolin B, Johansson B; Nordic Society of Paediatric Haematology, Oncology (NOPHO); Swedish Cytogenetic Leukaemia Study Group (SCLSG); NOPHO Leukaemia Cytogenetic Study Group (NLCSG). Forestier E, et al. Among authors: heyman m. Br J Haematol. 2008 Mar;140(6):665-72. doi: 10.1111/j.1365-2141.2008.06980.x. Epub 2008 Feb 1. Br J Haematol. 2008. PMID: 18241254 Free article.
Clinical and cytogenetic features of a population-based consecutive series of 285 pediatric T-cell acute lymphoblastic leukemias: rare T-cell receptor gene rearrangements are associated with poor outcome.
Karrman K, Forestier E, Heyman M, Andersen MK, Autio K, Blennow E, Borgström G, Ehrencrona H, Golovleva I, Heim S, Heinonen K, Hovland R, Johannsson JH, Kerndrup G, Nordgren A, Palmqvist L, Johansson B; Nordic Society of Pediatric Hematology, Oncology (NOPHO); Swedish Cytogenetic Leukemia Study Group (SCLSG); NOPHO Leukemia Cytogenetic Study Group (NLCSG). Karrman K, et al. Among authors: heyman m. Genes Chromosomes Cancer. 2009 Sep;48(9):795-805. doi: 10.1002/gcc.20684. Genes Chromosomes Cancer. 2009. PMID: 19530250
Oral methotrexate/6-mercaptopurine may be superior to a multidrug LSA2L2 Maintenance therapy for higher risk childhood acute lymphoblastic leukemia: results from the NOPHO ALL-92 study.
Schmiegelow K, Heyman M, Kristinsson J, Mogensen UB, Rosthøj S, Vettenranta K, Wesenberg F, Saarinen-Pihkala U; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: heyman m. J Pediatr Hematol Oncol. 2009 Jun;31(6):385-92. doi: 10.1097/MPH.0b013e3181a6e171. J Pediatr Hematol Oncol. 2009. PMID: 19648786 Clinical Trial.
DNA methylation for subtype classification and prediction of treatment outcome in patients with childhood acute lymphoblastic leukemia.
Milani L, Lundmark A, Kiialainen A, Nordlund J, Flaegstad T, Forestier E, Heyman M, Jonmundsson G, Kanerva J, Schmiegelow K, Söderhäll S, Gustafsson MG, Lönnerholm G, Syvänen AC. Milani L, et al. Among authors: heyman m. Blood. 2010 Feb 11;115(6):1214-25. doi: 10.1182/blood-2009-04-214668. Epub 2009 Nov 25. Blood. 2010. PMID: 19965625 Free article.
The degree of myelosuppression during maintenance therapy of adolescents with B-lineage intermediate risk acute lymphoblastic leukemia predicts risk of relapse.
Schmiegelow K, Heyman M, Gustafsson G, Lausen B, Wesenberg F, Kristinsson J, Vettenranta K, Schroeder H, Forestier E, Rosthoej S; Nordic Society of Paediatric Haematology and Oncology (NOPHO). Schmiegelow K, et al. Among authors: heyman m. Leukemia. 2010 Apr;24(4):715-20. doi: 10.1038/leu.2009.303. Epub 2010 Feb 4. Leukemia. 2010. PMID: 20130603 Free article.
In vitro cellular drug resistance adds prognostic information to other known risk-factors in childhood acute lymphoblastic leukemia.
Lönnerholm G, Thörn I, Sundström C, Frost BM, Flaegstad T, Heyman M, Jonsson OG, Harila-Saari A, Madsen HO, Porwit A, Schmiegelow K, Söderhäll S, Wesenberg F, Vettenranta K, Larsson R, Forestier E. Lönnerholm G, et al. Among authors: heyman m. Leuk Res. 2011 Apr;35(4):472-8. doi: 10.1016/j.leukres.2010.09.001. Epub 2010 Oct 18. Leuk Res. 2011. PMID: 20961616
624 results